Form 4: Enliven Therapeutics CFO Executes Pre-Planned Stock Option Exercise and Sale

Enliven Therapeutics' Chief Financial Officer, Benjamin Hohl, executed a pre-planned transaction involving the exercise of stock options and the subsequent sale of common stock on July 10, 2025.

Summary

• Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics, Inc. (ELVN), reported changes in his beneficial ownership of company securities.
• On July 10, 2025, Hohl exercised stock options to acquire 1,000 shares of Enliven Therapeutics common stock at an exercise price of $2.48 per share.
• Immediately following the option exercise, Hohl sold 1,000 shares of common stock at a weighted average sale price of $22.655 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan that Hohl adopted on June 26, 2023.
• The stock options exercised were fully vested and exercisable as of the transaction date.
• Following these reported transactions, Hohl directly holds 23,000 shares of common stock and 114,806 stock options.

Sentiment

Score: 5

Explanation: The document reports a routine, pre-planned insider transaction (exercise and sale) which is neutral in sentiment. It does not contain information that would significantly alter the perception of the company's financial health or future prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which demonstrates a planned and transparent approach to insider stock transactions.
• The sale price of $22.655 per share is significantly higher than the exercise price of $2.48, indicating a substantial gain on the exercised shares for the CFO.

Negatives

• The sale of shares by a Chief Financial Officer, even if pre-planned, could be perceived by some as a lack of confidence, though this is a common practice for liquidity or diversification purposes.

Risks

• No specific risks related to the company's operations, financial health, or strategic direction are mentioned in this Form 4 filing. The only potential 'risk' is the market's perception of insider selling, which is mitigated by the pre-existing Rule 10b5-1 plan.

Future Outlook

This document does not provide any forward-looking statements or guidance regarding the company's future performance, financial projections, or strategic outlook. It solely reports an insider trading transaction.

Management Comments

• "The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."
• "This transaction was executed in multiple trades at prices ranging from $22.59 to $22.72. The price reported above reflects the weighted average sale price."
• "The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."
• "All of the shares subject to this option are fully vested and exercisable as of the date hereof."

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information relevant to broader industry trends, competitive landscape analysis, or specific company-level developments. Such filings are common across all industries for publicly traded companies when insiders engage in pre-planned stock transactions.

Comparison to Industry Standards

• This document reports a standard insider transaction (exercise and sale) executed under a Rule 10b5-1 plan, which is a common and accepted practice for corporate insiders to manage their equity holdings while mitigating concerns about trading on material non-public information. There are no specific company or project results to compare against industry benchmarks in this filing.

Stakeholder Impact

• Shareholders: The sale of shares by a CFO, even if pre-planned, might be viewed with slight caution by some shareholders, but the existence of a Rule 10b5-1 plan mitigates concerns about opportunistic selling. The transaction itself is small relative to the company's overall market capitalization and is unlikely to have a material impact on share price.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate sale price upon request by the SEC staff, the Issuer, or a security holder of the Issuer.

Key Dates

Keywords

Enliven Therapeutics, ELVN, Form 4, Insider Trading, Stock Option Exercise, Stock Sale, Benjamin Hohl, CFO, Rule 10b5-1 Plan, Beneficial Ownership